Introduction

A groundbreaking project at the Cyprus Institute of Neurology and Genetics (CING) is set to transform the treatment landscape for beta-thalassemia, the most common inherited blood disorder in Cyprus. The initiative aims to deliver a one-time, curative therapy by leveraging advanced gene-editing technologies.

Path to Breakthrough

The Molecular Genetics Thalassaemia Department (MGTD) has announced the launch of the BETA-BET: Targeted Base Editing for Beta Thalassemia project. This ambitious program focuses on addressing the HBBIVSI-110 mutation, the primary genetic culprit behind the condition on the island. Beta-thalassemia arises from abnormalities in the β-globin gene (HBB), which plays a vital role in oxygen transportation through haemoglobin. Traditionally, patients have depended on lifelong blood transfusions to manage chronic anemia, a burden that this new therapy seeks to eliminate.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Expanding the Scope of Base Editing

The BETA-BET project, funded with a substantial budget of €198.83 million by the Research and Innovation Foundation (RIF) along with co-funding from the European Union and the Republic of Cyprus, pioneers the use of “base editing” technology. This method, comparable to a precise biological pencil and eraser, corrects single “letter” errors in the DNA sequence without inducing double-stranded breaks. An earlier preclinical study—conducted in collaboration with leading institutions across Greece and Germany—demonstrated the potential of these tools to effectively restore the production of functional red blood cells in individuals homozygous for the HBBIVSI-110 mutation.

Innovative Delivery System

Beyond expanding the patient group to include compound heterozygotes, whose prevalence significantly exceeds that of homozygotes in many regions, the project introduces a revolutionary delivery mechanism. Engineered virus-like particles (eVLPs) are being developed to function as microscopic delivery drones, transporting gene-editing complexes directly to blood-forming stem cells. This strategy could simplify treatment administration to a single injection, thereby eliminating the current, complicated process of ex vivo stem cell manipulation.

Collaborative Leadership and Global Partnerships

Under the expert guidance of Dr Petros Patsali, Associate Scientist at MGTD, and a team of renowned researchers, the project draws on a network of national and international partners. Esteemed collaborators include institutions such as George Papanikolaou Hospital, the Aristotle University of Thessaloniki, and the University of Freiburg, among others. These partnerships not only bolster the project’s scientific rigor but also enhance its global relevance, particularly in high-incidence areas like Greece and Egypt.

Conclusion

By extending the precision of base editing to a wider patient demographic and integrating novel delivery systems, the BETA-BET initiative represents a significant advance in gene therapy. This innovative approach could eventually provide a transformative, one-time treatment for thousands of patients, marking a milestone in the pursuit of a definitive cure for thalassemia.